Immutep Ltd has released a press release.
Immutep receives FDA feedback for Efti development in MBC
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Australian Patent Granted for Efti with PD-1 Inhibitors
- Immutep Advances IMP761 Manufacturing
- Good safety reported from 1st five patients in INSIGHT-003
- Phase II TACTI-002 trial recruitment successfully completed
- Immutep Global Webcast Slides to Discuss Clinical Results
Later from Immutep
- Japanese patent granted for LAG-3 antibody LAG525
- Immutep announces publication of ELCC 2022 abstract
- Efti with Keytruda shows encouraging activity in lung cancer
- Immutep to announce new TACTI-002 data at ASCO 2022
- New & significant data from AIPAC phase 2b trial in MBC
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep